Effectiveness and Safety of Bevacizumab(BV) plus FOLFIRI as First-Line Metastatic Colorectal Cancer (mCRC) Treatment: ETNA Cohort Study

被引：0
|
作者：
Fourrier-Reglat, A. [1 ]
Rouyer, M. [1 ]
Benichou, J. [2 ]
Balestra, A. [1 ]
Bernard, M. A. [1 ]
Grelaud, A. [1 ]
Smith, D. [3 ]
Ravaud, A. [3 ]
Moore, N. [1 ]
机构：
[1] Bordeaux Univ, Bordeaux, France
[2] Rouen Hosp, Rouen, France
[3] Bordeaux Hosp, Bordeaux, France
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2010年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
64
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [1] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [2] Effectiveness and safety of bevacizumab plus FOLFIRI in first-line metastatic colorectal cancer (mCRC) after 24 months of follow-up for the ETNA cohort study
    Smith, D.
    Rouyer, M.
    Becouarn, Y.
    Michel, P.
    Guimbaud, R.
    Tubiana-Mathieu, N.
    Viret, F.
    Ravaud, A.
    Moore, N.
    Fourrier-Reglat, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort
    Rouyer, Magali
    Fourrier-Reglat, Annie
    Smith, Denis
    Becouarn, Yves
    Guimbaud, Rosine
    Tubiana-Mathieu, Nicole
    Robinson, Philip
    Jove, Jeremy
    Grelaud, Angela
    Noize, Pernelle
    Moore, Nicholas
    Ravaud, Alain
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2016, 7 (03) : 187 - 194
  • [4] Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV
    Muro, Kei
    Yamanaka, Takeharu
    Suenaga, Mitsukuni
    Nishina, Tomohiro
    Yasul, Hisateru
    Ura, Takashi
    Denda, Tadamichi
    Ikeda, Junichi
    Esakl, Taito
    Nishisaki, Hogara
    Takano, Yoshinao
    Kondo, Ken
    Takeda, Koji
    Takahashi, Yasuo
    Endo, Kazuya
    Sugiyama, Yasuyuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Effectiveness and safety in very elderly patients treated by bevacizumab (BV) plus chemotherapy in first-line therapy of metastatic colorectal cancer: Results of ETNA, a French cohort study
    Smith, D.
    Rouyer, M.
    Noize, P.
    Lassalle, R.
    Bernard, O.
    Burki, F.
    Guichard, P.
    Ravaud, A.
    Moore, N.
    Fourrier-Raglat, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [6] VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Santini, D.
    Bencardino, K.
    Manzoni, M.
    Falcone, A.
    Graziano, F.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 357 - 357
  • [7] VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Masi, G.
    Schirripa, M.
    Spoto, C.
    Galluccio, N.
    Vincenzi, B.
    Santini, D.
    Bencardino, K.
    Ricci, V
    Catalano, V
    Manzoni, M.
    Danova, M.
    Tonini, G.
    Magnani, M.
    Falcone, A.
    Graziano, F.
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [8] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI COMPARED TO BV PLUS FOLFIRI AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): PRELIMINARY SAFETY RESULTS OF THE TRIBE STUDY BY THE GRUPPO ONCOLOGICO NORD-OVEST (GONO)
    Masi, G.
    Loupakis, F.
    Frustaci, S.
    Tuzi, A.
    Passalacqua, R.
    Cupini, S.
    Ribecco, A.
    Andreuccetti, M.
    Boni, L.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 197 - 197
  • [9] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
    Huang, Ching-Wen
    Yeh, Yung-Sung
    Ma, Cheng-Jen
    Tsai, Hsiang-Lin
    Chen, Chao-Wen
    Huang, Ming-Yii
    Lu, Chien-Yu
    Wu, Jeng-Yih
    Wang, Jaw Yuan
    [J]. CHEMOTHERAPY, 2017, 62 (01): : 80 - 84
  • [10] FOLFOXIFI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO).
    Falcone, A.
    Loupakis, F.
    Cupini, S.
    Cortesi, E.
    Buonadonna, A.
    Tomasello, G.
    Banzi, M.
    Ronzoni, M.
    Zaniboni, A.
    Masi, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345